Sanofi/Regeneron’s one-two punch on PCSK9 price and health data wins a key convert as Express Scripts creates exclusive formulary deal
Just 7 weeks after Sanofi $SNY and Regeneron $REGN flagged pivotal data on a clear mortality benefit to be had from its PCSK9 cardio drug Praluent, they’re back with a chummy public selfie with Express Scripts that swaps a new discount price in exchange for a pledge to dismantle any hurdles that could prevent the PBM’s 20 million members from taking advantage of it.
Nobody’s talking specifics here, but in March Sanofi/Regeneron pledged to cut its price to $4,460 to $7,975 a year for payers who are willing to stop throwing up roadblocks to this drug, dropping to a price that on the low end is not much higher than the $10-a-day cost of the old generation of statins before they went generic. At the high end, it still marks a sharp drop from the $14,000 wholesale price that had been the market standard used to peg discounts against.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
